These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 39360822)
1. Prolonged Omicron-specific B cell maturation alleviates immune imprinting induced by SARS-CoV-2 inactivated vaccine. Yisimayi A; Song W; Wang J; Jian F; Yu Y; Chen X; Xu Y; An R; Wang Y; Wang J; Sun H; Wang P; Yu L; Shao F; Jin R; Shen Z; Wang Y; Cao Y Emerg Microbes Infect; 2024 Dec; 13(1):2412623. PubMed ID: 39360822 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients. Chen Y; Zhao T; Chen L; Jiang G; Geng Y; Li W; Yin S; Tong X; Tao Y; Ni J; Lu Q; Ning M; Wu C mBio; 2024 Apr; 15(4):e0240723. PubMed ID: 38456703 [TBL] [Abstract][Full Text] [Related]
3. Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting. Yisimayi A; Song W; Wang J; Jian F; Yu Y; Chen X; Xu Y; Yang S; Niu X; Xiao T; Wang J; Zhao L; Sun H; An R; Zhang N; Wang Y; Wang P; Yu L; Lv Z; Gu Q; Shao F; Jin R; Shen Z; Xie XS; Wang Y; Cao Y Nature; 2024 Jan; 625(7993):148-156. PubMed ID: 37993710 [TBL] [Abstract][Full Text] [Related]
4. Finite immune imprinting on neutralizing antibody responses to Omicron subvariants by repeated vaccinations. Song XD; Yang GJ; Shi C; Jiang XL; Wang XJ; Zhang YW; Wu J; Zhao LX; Wang MM; Chen RR; He XJ; Dai EH; Shen Y; Gao HX; Dong G; Ma MJ Int J Infect Dis; 2024 Oct; 147():107198. PubMed ID: 39117174 [TBL] [Abstract][Full Text] [Related]
5. Repeated Omicron infection dampens immune imprinting from previous vaccination and induces broad neutralizing antibodies against Omicron sub-variants. Gong X; Peng L; Wang F; Liu J; Tang Y; Peng Y; Niu S; Yin J; Guo L; Lu H; Liu Y; Yang Y J Infect; 2024 Aug; 89(2):106208. PubMed ID: 38908522 [TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial. Poh XY; Torres-Ruesta A; Yoong T; Wong N; Tan CW; Rouers A; Chavatte JM; Goh YS; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Neo V; Kam IKJ; Huang Y; Hor PX; Loh CY; ; Yeoh AY; Lim DRX; Chia W; Ren EC; Lin RTP; Fong SW; Renia L; Lye DC; Wang LF; Ng LFP; Young BE Vaccine; 2024 Nov; 42(25):126275. PubMed ID: 39241318 [TBL] [Abstract][Full Text] [Related]
8. Fourth dose bivalent COVID-19 vaccines outperform monovalent boosters in eliciting cross-reactive memory B cells to Omicron subvariants. Fryer HA; Geers D; Gommers L; Zaeck LM; Tan NH; Jones-Freeman B; Goorhuis A; Postma DF; Visser LG; Hogarth PM; Koopmans MPG; GeurtsvanKessel CH; O'Hehir RE; van der Kuy PHM; de Vries RD; van Zelm MC J Infect; 2024 Oct; 89(4):106246. PubMed ID: 39127451 [TBL] [Abstract][Full Text] [Related]
9. Immunity against conserved epitopes dominates after two consecutive exposures to SARS-CoV-2 Omicron BA.1. Muik A; Quandt J; Lui BG; Bacher M; Lutz S; Grünenthal M; Toker A; Grosser J; Ozhelvaci O; Blokhina O; Shpyro S; Vogler I; Salisch N; Türeci Ö; Sahin U Cell Rep; 2024 Aug; 43(8):114567. PubMed ID: 39097927 [TBL] [Abstract][Full Text] [Related]
10. Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections. Jeong HW; Rollon R; Kim SM; Gil J; Casel MA; Jang H; Choi JH; Jang SG; Lazarte JC; Kim HS; Kim JH; Choi YK Influenza Other Respir Viruses; 2024 Oct; 18(10):e70000. PubMed ID: 39377176 [TBL] [Abstract][Full Text] [Related]
11. Omicron breakthrough infections after triple-dose inactivated COVID-19 vaccination: A comprehensive analysis of antibody and T-cell responses. Xiang T; Quan X; Jia H; Wang H; Liang B; Li S; Wang X; Li H; Feng X; Fan L; Xu L; Wang T; Xiong S; Yang D; Liu J; Zheng X Immunology; 2024 Jun; 172(2):313-327. PubMed ID: 38462236 [TBL] [Abstract][Full Text] [Related]
12. Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters. Bricker TL; Joshi A; Soudani N; Scheaffer SM; Patel N; Guebre-Xabier M; Smith G; Diamond MS; Boon ACM J Virol; 2024 Mar; 98(3):e0120623. PubMed ID: 38305154 [TBL] [Abstract][Full Text] [Related]
13. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages. Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791 [TBL] [Abstract][Full Text] [Related]
14. Individuals carrying the HLA-B*15 allele exhibit favorable responses to COVID-19 vaccines but are more susceptible to Omicron BA.5.2 and XBB.1.16 infection. Meng L; Pan Y; Liu Y; He R; Sun Y; Wang C; Fei L; Zhu A; Wang Z; An Y; Wu Y; Diao B; Chen Y Front Immunol; 2024; 15():1440819. PubMed ID: 39257586 [TBL] [Abstract][Full Text] [Related]
15. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023 [TBL] [Abstract][Full Text] [Related]
16. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479 [TBL] [Abstract][Full Text] [Related]
17. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial. Poh XY; Lee IR; Tan CW; Chavatte JM; Fong SW; Goh YS; Rouers A; Wong N; Torres-Ruesta A; Mah SYY; Yeoh AYY; Gandhi M; Rahman N; Chin YQ; Lim JJ; Yoong TJK; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim DRX; Chia W; Renia L; Ren EC; Lin RTP; Lye DC; Wang LF; Ng LFP; Young BE EBioMedicine; 2024 Sep; 107():105275. PubMed ID: 39137572 [TBL] [Abstract][Full Text] [Related]
18. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents. Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM Front Immunol; 2024; 15():1372193. PubMed ID: 38812507 [TBL] [Abstract][Full Text] [Related]
19. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Wang X; Zhao X; Song J; Wu J; Zhu Y; Li M; Cui Y; Chen Y; Yang L; Liu J; Zhu H; Jiang S; Wang P Emerg Microbes Infect; 2022 Dec; 11(1):477-481. PubMed ID: 35034583 [TBL] [Abstract][Full Text] [Related]
20. Immune Profile and Clinical Outcome of Breakthrough Cases After Vaccination With an Inactivated SARS-CoV-2 Vaccine. Duarte LF; Gálvez NMS; Iturriaga C; Melo-González F; Soto JA; Schultz BM; Urzúa M; González LA; Vázquez Y; Ríos M; Berríos-Rojas RV; Rivera-Pérez D; Moreno-Tapia D; Pacheco GA; Vallejos OP; Hoppe-Elsholz G; Navarrete MS; Rojas Á; Fasce RA; Fernández J; Mora J; Ramírez E; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Bueno SM; Kalergis AM Front Immunol; 2021; 12():742914. PubMed ID: 34659237 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]